SCHEMBL4477641

SCHEMBL4477641

[C]1C=CC2C=CC=CC2O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19743847 0.60
SCHEMBL4477639 0.60
SCHEMBL2044223 0.60
SCHEMBL12937701 0.60
SCHEMBL7139212 0.60
SCHEMBL14413181 0.60
SCHEMBL1246040 0.56
SCHEMBL3767412 0.55
SCHEMBL9715235 0.55
SCHEMBL14533802 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578425-B1 SUBSTITUTED 1-PIPERIDIN-3-YL-4-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2007-11-21 EP claimed
US-20060252747-A1 Substitituted 1-piperidin-3-yl-piperidin 4-yl-piperazine derivatives and their use as neurokinin auantagonists JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-09 US claimed
US-7572786-B2 Irritable bowel syndrome; tachykinin mediated condition such as schizophrenia, emesis, anxiety, depression, irritable bowel syndrome, circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorder or nociception JANSSEN PHARMACEUTICA, N.V. (BE) 2009-08-11 US disclosed
EP-1578425-B1 SUBSTITUTED 1-PIPERIDIN-3-YL-4-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2007-11-21 EP disclosed
US-20060252747-A1 Substitituted 1-piperidin-3-yl-piperidin 4-yl-piperazine derivatives and their use as neurokinin auantagonists JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-09 US disclosed